Xiangxue Pharmaceutical (300147) — Tangible Net Worth Ratio
Xiangxue Pharmaceutical (300147) has a Tangible Net Worth Ratio of -2128.5% as of December 2025. This metric is calculated by deducting intangible assets (CN¥979.34 Million) from net assets (CN¥43.95 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. For live market cap and overall valuation, see Xiangxue Pharmaceutical stock valuation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Xiangxue Pharmaceutical Tangible Net Worth Ratio (2007–2025)
This chart shows how Xiangxue Pharmaceutical's Tangible Net Worth Ratio has changed across 19 annual periods from 2007 to 2025. As of December 2025, the ratio stands at -2128.5%, reflecting net assets of CN¥43.95 Million with intangible assets of CN¥979.34 Million CNY. Also explore Xiangxue Pharmaceutical annual equity growth to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Xiangxue Pharmaceutical (2007–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Xiangxue Pharmaceutical from 2007 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See financial agility of Xiangxue Pharmaceutical to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -2128.5% | CN¥43.95 Million | CN¥979.34 Million | CN¥6.75 Billion | ▼ -2154.9 pp |
| 2024 | 26.3% | CN¥1.44 Billion | CN¥1.06 Billion | CN¥7.50 Billion | ▼ -15.1 pp |
| 2023 | 41.4% | CN¥2.31 Billion | CN¥1.36 Billion | CN¥8.28 Billion | ▼ -10.1 pp |
| 2022 | 51.5% | CN¥2.82 Billion | CN¥1.37 Billion | CN¥9.35 Billion | ▼ -10.5 pp |
| 2021 | 62.0% | CN¥3.76 Billion | CN¥1.43 Billion | CN¥11.38 Billion | ▼ -15.1 pp |
| 2020 | 77.1% | CN¥4.25 Billion | CN¥973.96 Million | CN¥9.78 Billion | ▼ -5.3 pp |
| 2019 | 82.4% | CN¥4.11 Billion | CN¥721.63 Million | CN¥8.46 Billion | ▲ +1.8 pp |
| 2018 | 80.6% | CN¥4.01 Billion | CN¥778.35 Million | CN¥8.63 Billion | ▼ -5.0 pp |
| 2017 | 85.6% | CN¥3.88 Billion | CN¥559.82 Million | CN¥9.44 Billion | ▼ -3.5 pp |
| 2016 | 89.1% | CN¥3.68 Billion | CN¥401.17 Million | CN¥7.99 Billion | ▼ -2.4 pp |
| 2015 | 91.5% | CN¥3.55 Billion | CN¥301.95 Million | CN¥4.65 Billion | ▲ +4.2 pp |
| 2014 | 87.3% | CN¥1.87 Billion | CN¥238.01 Million | CN¥3.59 Billion | ▲ +0.1 pp |
| 2013 | 87.2% | CN¥1.71 Billion | CN¥219.59 Million | CN¥3.47 Billion | ▼ -2.6 pp |
| 2012 | 89.7% | CN¥1.54 Billion | CN¥157.82 Million | CN¥2.95 Billion | ▼ -2.2 pp |
| 2011 | 92.0% | CN¥1.42 Billion | CN¥113.96 Million | CN¥1.92 Billion | ▼ -3.1 pp |
| 2010 | 95.1% | CN¥1.37 Billion | CN¥67.38 Million | CN¥1.85 Billion | ▲ +15.9 pp |
| 2009 | 79.2% | CN¥337.62 Million | CN¥70.28 Million | CN¥698.31 Million | ▲ +16.4 pp |
| 2008 | 62.8% | CN¥196.54 Million | CN¥73.15 Million | CN¥551.47 Million | ▼ -12.6 pp |
| 2007 | 75.4% | CN¥191.45 Million | CN¥47.07 Million | CN¥553.43 Million | — |